共 37 条
[1]
Murthy SB(2016)Nosocomial infections and outcomes after intracerebral hemorrhage: a population-based study Neurocrit Care 25 178-184
[2]
Moradiya Y(2009)The use of carbapenems in the treatment of serious infections J Intensive Care Med 24 230-241
[3]
Shah J(2000)Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit Clin Microbiol Infect 6 294-302
[4]
Merkler AE(2013)Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants Pediatr Infect Dis J 32 748-753
[5]
Mangat HS(2014)A retrospective study on the incidence of seizures among neurosurgical patients who treated with imipenem/cilastatin or meropenem Curr Pharm Biotechnol 15 685-690
[6]
Iadacola C(2009)Safety of imipenem/cilastatin in neurocritical care patients Neurocrit Care 10 403-407
[7]
Hanley DF(1976)Prediction of creatinine clearance from serum creatinine Nephron 16 31-41
[8]
Kamel H(2016)Vancomycin pharmacokinetic parameters in patients with hemorrhagic stroke Neurocrit Care 2016 250-257
[9]
Ziai WC(2017)Pharmacokinetic/pharmacodynamic analysis of meropenem for the treatment of nosocomial pneumonia in intracerebral hemorrhage patients by Monte Carlo simulation Ann Pharmacother 51 970-975
[10]
Baughman RP(1986)Cerebrospinal fluid penetration of imipenem and cilastatin (primaxin) in children with central nervous system infections Antimicrob Agents Chemother 29 670-674